Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers.

Avidity maturation of humoral response following primary and booster doses of BNT162b2 mRNA vaccine among nursing home residents and healthcare workers.

Publication date: Dec 01, 2024

Infections, despite vaccination, can be clinically consequential for frail nursing home residents (NHR). Poor vaccine-induced antibody quality may add risk for such subsequent infections and more severe disease. We assessed antibody binding avidity, as a surrogate for antibody quality, among NHR and healthcare workers (HCW). We longitudinally sampled 112 NHR and 52 HCWs who received the BNT162b2 mRNA vaccine after each dose up to the Wuhan-BA. 4/5-based Omicron bivalent boosters. We quantified anti-spike, anti-receptor binding domain (RBD), and avidity levels to the ancestral Wuhan, Delta, and Omicron BA. 1 & 4/5 strains. The primary vaccination series produced substantial anti-spike and RBD levels which were low in avidity against all strains tested. Antibody avidity progressively increased in the 6-8 months that followed. Avidity significantly increased after the 1st booster but not for subsequent boosters. This study underscores the importance of booster vaccination among NHR and HCWs. The 1st booster dose increases avidity, increasing vaccine-induced functional antibody. The higher cross-reactivity of higher avidity antibodies to other SARS-CoV-2 strains should translate to better protection from ever-evolving strains. Higher avidities may help explain how the vaccine’s protective effects persist despite waning antibody titers after each vaccine dose.

Open Access PDF

Concepts Keywords
Bnt162b2 Adult
Home Affinity maturation
Nursing Aged
Severe Aged, 80 and over
Vaccine Antibodies, Viral
Antibodies, Viral
Antibody Affinity
Avidity
Bivalent boosters
BNT162 Vaccine
BNT162 Vaccine
COVID-19
COVID-19
COVID-19 Vaccines
COVID-19 Vaccines
Female
Health Personnel
Healthcare workers
Humans
Immunity, Humoral
Immunization, Secondary
Longitudinal Studies
Male
Middle Aged
Nursing home residents
Nursing Homes
Omicron
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus

Semantics

Type Source Name
disease MESH Infections
disease IDO quality
drug DRUGBANK Tropicamide
disease MESH COVID 19
disease MESH morbidity
drug DRUGBANK Angiotensin II
disease IDO infection
drug DRUGBANK Piroxicam
drug DRUGBANK Coenzyme M
drug DRUGBANK Etoperidone
disease MESH emergency
disease IDO history
disease MESH sid
disease IDO assay
drug DRUGBANK Immune Globulin Human
drug DRUGBANK Urea
disease IDO blood
disease IDO production
disease IDO reagent
disease MESH re infection
disease IDO process
drug DRUGBANK Indoleacetic acid
disease IDO cell
disease IDO protein
drug DRUGBANK Dihydrocodeine
disease MESH influenza
pathway REACTOME Reproduction
disease MESH Death
disease MESH Infectious Diseases
disease MESH retirement
drug DRUGBANK Esomeprazole
disease MESH measles
pathway KEGG Measles
disease MESH coronavirus infections
drug DRUGBANK Cysteamine
disease MESH breakthrough infection
disease IDO humoral immune response

Original Article

(Visited 4 times, 1 visits today)